Posts by: Marisa Wexler

News

Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans ... Read more

January 24, 2019

Researchers Develop Computer Model to Predict Prostate Cancer Progression

News

A new study has yielded a new computer model to understand the progression of prostate cancer, which may yield insights into understanding the disease and providing care for patients. ... Read more

January 14, 2019

Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men, Study Suggests

News

Black men diagnosed with low-risk prostate cancer are two times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting ... Read more

Posts by: Marisa Wexler

Marisa Wexler

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

Researchers Develop Computer Model to Predict Prostate Cancer Progression

Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men, Study Suggests

Pin It on Pinterest